

## REFERENSI

- Abcouwer, S. F. 2013. Angiogenic factors and cytokines in diabetic retinopathy. *J. Clin. Cell. Immunol.*, 1.
- Ahmed, I. & Patton, T. 1985. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. *Invest. Ophthalmol. Vis. Sci.*, 26, 584-587.
- Ajlan, R. S., Silva, P. S. & Sun, J. K. Vascular endothelial growth factor and diabetic retinal disease. *Seminars in ophthalmology*, 2016. Taylor & Francis, 40-48.
- Alasil, T., Keane, P. A., Updike, J. F., Dustin, L., Ouyang, Y., Walsh, A. C. & Sadda, S. R. 2010. Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. *Ophthalmology*, 117, 2379-2386.
- Antonetti, D. A., Klein, R. & Gardner, T. W. 2012. Diabetic Retinopathy. *N. Engl. J. Med.*, 366, 1227-1239.
- Arevalo, J. F. 2013. Diabetic macular edema: Current management 2013. *World J. Diabetes*, 4, 231.
- Ayalasomayajula, S. P. & Kompella, U. B. 2003. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. *Eur. J. Pharmacol.*, 458, 283-289.
- Bandello, F., Casalino, G., Loewenstein, A., Goldstein, M., Pelayes, D. & Parodi, M. B. 2014. Pharmacological approach to diabetic macular edema. *Ophthalmic Res.*, 51, 88-95.
- Bandello, F., Parodi, M. B., Lanzetta, P., Loewenstein, A., Massin, P., Menchini, F. & Veritti, D. 2010. Diabetic macular edema. *Dev. Ophthalmol.*, 47, 73-110.
- Bandello, F., Parodi, M. B., Lanzetta, P., Loewenstein, A., Massin, P., Menchini, F. & Veritti, D. 2017. Diabetic macular edema. *Dev. Ophthalmol.*, 58, 102-138.
- Bandello, F., Pognuz, R., Polito, A., Pirracchio, A., Menchini, F. & Ambesi, M. Diabetic macular edema: classification, medical and laser therapy. *Seminars in ophthalmology*, 2003. 251-258.
- Barber, A. J. 2003. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. *Prog. Neuropsychopharmacol. Biol. Psychiatry*, 27, 283-290.
- Barber, A. J. & Baccouche, B. 2017. Neurodegeneration in diabetic retinopathy: potential for novel therapies. *Vision Res.*, 139, 82-92.
- Barber, A. J., Gardner, T. W. & Abcouwer, S. F. 2011. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. *Invest. Ophthalmol. Vis. Sci.*, 52, 1156-1163.
- Barber, A. J., Lieth, E., Khin, S. A., Antonetti, D. A., Buchanan, A. G. & Gardner, T. W. 1998. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. *J. Clin. Investig.*, 102, 783-791.
- Bearse, M. A. & Ozawa, G. Y. 2014. Multifocal electroretinography in diabetic retinopathy and diabetic macular edema. *Curr. Diab. Rep.*, 14, 526.
- Bezzina, A. D. & Carbonaro, F. 2019. Factors Predicting Treatment Response in Anti-Vascular Endothelial Growth Factor Naïve Diabetic Macular Edema Patients Treated with Intravitreal Bevacizumab. *J. Ocul. Pharmacol. Ther.*, 35, 551-557.
- Biallostowski, C., Van Velthoven, M. E., Michels, R. P., Schlingemann, R. O., Devries, J. H. & Verbraak, F. D. 2007. Decreased optical coherence tomography-measured pericentral retinal thickness in patients with diabetes mellitus type 1 with minimal diabetic retinopathy. *Br. J. Ophthalmol.*, 91, 1135-1138.

- Bodaghi, B. 2008. Diclofenac sodium 0.1% ophthalmic solution: update on pharmacodynamics, clinical interest and safety profile. *Expert Rev. Ophthalmol.*, 3, 139-148.
- Bonnin, S., Tadayoni, R., Erginay, A., Massin, P. & Dupas, B. 2015. Correlation between ganglion cell layer thinning and poor visual function after resolution of diabetic macular edema. *Invest. Ophthalmol. Vis. Sci.*, 56, 978-982.
- Boyer, D. S., Hopkins, J. J., Sorof, J. & Ehrlich, J. S. 2013. Anti-vascular endothelial growth factor therapy for diabetic macular edema. *Ther. Adv. Endocrinol. Metab.*, 4, 151-169.
- Bronson-Castain, K. W., Bearse Jr, M. A., Neuvillie, J., Jonasdottir, S., King-Hooper, B., Barez, S., Schneck, M. E. & Adams, A. J. 2009. Adolescents with type 2 diabetes: Early indications of focal retinal neuropathy, retinal thinning and venular dilation. *Retina (Philadelphia, Pa.)*, 29, 618.
- Carpineto, P., Toto, L., Aloia, R., Ciciarelli, V., Borrelli, E., Vitacolonna, E., Di Nicola, M., Di Antonio, L. & Mastropasqua, R. 2016. Neuroretinal alterations in the early stages of diabetic retinopathy in patients with type 2 diabetes mellitus. *Eye*, 30, 673-679.
- Cavan, D., Makaroff, L., Da Rocha Fernandes, J., Sylvanowicz, M., Ackland, P., Conlon, J., Chaney, D., Malhi, A. & Barratt, J. 2017. The diabetic retinopathy barometer study: global perspectives on access to and experiences of diabetic retinopathy screening and treatment. *Diabetes Res. Clin. Pract.*, 129, 16-24.
- Cheng, L., Wang, M., Deng, J., Lv, M., Jiang, W., Xiong, S., Sun, S., Zhu, J., Zou, H. & He, X. 2019. Macular ganglion cell-inner plexiform layer, ganglion cell complex, and outer retinal layer thicknesses in a large cohort of Chinese children. *Invest. Ophthalmol. Vis. Sci.*, 60, 4792-4802.
- Ciloglu, E., Unal, F. & Dogan, N. C. 2020. Changes in the ganglion cell complex thickness after anti-VEGF treatment for diabetic macular edema. *Arq. Bras. Oftalmol.*, 83, 372-377.
- Darma, W. S. & Virgana, R. 2019. Evaluation of Thickness of Ganglion Cell Layer with Inner Plexiform Layer in Patients With Diabetic Retinopathy. *Methods*, 2019.
- Das, R., Spence, G., Hogg, R. E., Stevenson, M. & Chakravarthy, U. 2018. Disorganization of inner retina and outer retinal morphology in diabetic macular edema. *JAMA Ophthalmol.*, 136, 202-208.
- Deák, G. G., Schmidt-Erfurth, U. M. & Jampol, L. M. 2018. Correlation of Central Retinal Thickness and Visual Acuity in Diabetic Macular Edema. *JAMA Ophthalmol.*, 136, 1215-1216.
- Debut, D. C. & Somfai, G. M. 2010. Early detection of retinal thickness changes in diabetes using optical coherence tomography. *Med. Sci. Monit.*, 16, MT15-MT21.
- Durairaj, C. 2016. Ocular pharmacokinetics. *Pharmacologic Therapy of Ocular Disease*. Springer.
- Ehrlich, R., Harris, A., Ciulla, T. A., Kheradiya, N., Winston, D. M. & Wirosko, B. 2010. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. *Acta Ophthalmol. (Copenh.)*, 88, 279-291.
- Ellis, P. P., Pfoff, D. S., Bloedow, D. C. & Riegel, M. 1994. Intraocular diclofenac and flurbiprofen concentrations in human aqueous humor following topical application. *J. Ocul. Pharmacol. Ther.*, 10, 677-682.
- Entezari, M., Ramezani, A., Nikkhah, H. & Yaseri, M. 2017. The effect of topical sodium diclofenac on macular thickness in diabetic eyes after phacoemulsification: a randomized controlled trial. *Int. Ophthalmol.*, 37, 13-18.
- Fernández, D. C., Somfai, G., Tátrai, E., Ranganathan, S., Yee, D., Ferencz, M. & Smiddy, W. 2008. Potentiality of intraretinal layer segmentation to locally detect early retinal changes in patients with diabetes mellitus using optical coherence tomography. *Invest. Ophthalmol. Vis. Sci.*, 49, 2751-2751.

- Flaxel, C., Schain, M. B., Hamon, S. C. & Francis, P. J. 2012. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. *Retina*, 32, 417-423.
- Gastinger, M. J., Singh, R. S. & Barber, A. J. 2006. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. *Invest. Ophthalmol. Vis. Sci.*, 47, 3143-3150.
- Gaudana, R., Ananthula, H. K., Parenky, A. & Mitra, A. K. 2010. Ocular drug delivery. *The AAPS journal*, 12, 348-360.
- Ghanbari, H., Kianersi, F., Sonbolestan, S. A., Abtahi, M.-A., Akbari, M., Abtahi, Z.-A. & Abtahi, S.-H. 2017. Intravitreal Diclofenac plus Bevacizumab versus Bevacizumab alone in treatment-naive diabetic macular edema: a randomized double-blind clinical trial. *Int. Ophthalmol.*, 37, 867-874.
- Gillies, M. C., Sutter, F. K., Simpson, J. M., Larsson, J., Ali, H. & Zhu, M. 2006. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. *Ophthalmology*, 113, 1533-1538.
- Gologorsky, D., Thanos, A. & Vavvas, D. 2012. Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy. *Mediators Inflamm.*, 2012.
- Gomi, F., Sawa, M., Tsujikawa, M. & Nishida, K. 2012. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. *Retina*, 32, 1804-1810.
- Hammes, H.-P., Federoff, H. J. & Brownlee, M. 1995. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. *Mol. Med.*, 1, 527-534.
- Hermann, M. M., Üstündag, C. & Diestelhorst, M. 2010. Electronic compliance monitoring of topical treatment after ophthalmic surgery. *Int. Ophthalmol.*, 30, 385-390.
- Hernández, C. & Simó, R. 2012. Neuroprotection in diabetic retinopathy. *Curr. Diab. Rep.*, 12, 329-337.
- Jeon, S. & Lee, W. K. 2014. Effect of intravitreal bevacizumab on diabetic macular edema with hard exudates. *Clin. Ophthalmol.*, 8, 1479.
- Kass, M. A., Gordon, M., Morley, R. E., Meltzer, D. W. & Goldberg, J. J. 1987. Compliance with topical timolol treatment. *Am. J. Ophthalmol.*, 103, 188-193.
- Kass, M. A., Meltzer, D. W., Gordon, M., Cooper, D. & Goldberg, J. 1986. Compliance with topical pilocarpine treatment. *Am. J. Ophthalmol.*, 101, 515-523.
- Kern, T. S., Miller, C. M., Du, Y., Zheng, L., Mohr, S., Ball, S. L., Kim, M., Jamison, J. A. & Bingaman, D. P. 2007. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. *Diabetes*, 56, 373-379.
- Kerrigan, L. A., Zack, D. J., Quigley, H. A., Smith, S. D. & Pease, M. E. 1997. TUNEL-positive ganglion cells in human primary open-angle glaucoma. *Arch. Ophthalmol.*, 115, 1031-1035.
- Kim, D. Y., Jung, S. Y., Kim, C. J., Sung, Y. H. & Kim, J. D. 2013. Treadmill exercise ameliorates apoptotic cell death in the retinas of diabetic rats. *Mol. Med. Report.*, 7, 1745-1750.
- Kim, S. J., Flach, A. J. & Jampol, L. M. 2010a. Nonsteroidal anti-inflammatory drugs in ophthalmology. *Surv. Ophthalmol.*, 55, 108-133.
- Kim, S. J., Toma, H. S., Barnett, J. M. & Penn, J. S. 2010b. Ketorolac inhibits choroidal neovascularization by suppression of retinal VEGF. *Exp. Eye Res.*, 91, 537-543.
- Kim, S. Y., Johnson, M. A., Mcleod, D. S., Alexander, T., Otsuji, T., Steidl, S. M., Hansen, B. C. & Luty, G. A. 2004. Retinopathy in monkeys with spontaneous type 2 diabetes. *Invest. Ophthalmol. Vis. Sci.*, 45, 4543-4553.

- Klaassen, I., Van Noorden, C. J. & Schlingemann, R. O. 2013. Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. *Prog. Retin. Eye Res.*, 34, 19-48.
- Lang, G. E. 2012. Diabetic macular edema. *Ophthalmologica*, 227, 21-29.
- Lechner, J., O'leary, O. E. & Stitt, A. W. 2017. The pathology associated with diabetic retinopathy. *Vision Res.*, 139, 7-14.
- Lee, R., Wong, T. Y. & Sabanayagam, C. 2015. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. *Eye Vis.*, 2, 17.
- Lee, Y. P., Ju, Y.-S. & Choi, D. G. 2018. Ganglion cell-inner plexiform layer thickness by swept-source optical coherence tomography in healthy Korean children: Normative data and biometric correlations. *Sci. Rep.*, 8, 1-5.
- Lim, H. B., Lee, W. H., Jo, Y. J. & Kim, J. Y. 2018. Interocular Asymmetry of the Ganglion Cell–inner Plexiform Layer in Diabetic Retinopathy. *Optom. Vis. Sci.*, 95, 594-601.
- Lim, H. B., Shin, Y. I., Lee, M. W., Koo, H., Lee, W. H. & Kim, J. Y. 2020. Ganglion Cell–Inner Plexiform Layer Damage in Diabetic Patients: 3-Year Prospective, Longitudinal, Observational Study. *Sci. Rep.*, 10, 1-9.
- M. Jousen, A., Poulaki, V., Mitsiades, N., Kirchhof, B., Koizumi, K., Döhmen, S. & P. Adamis, A. 2002. Nonsteroidal anti - inflammatory drugs prevent early diabetic retinopathy via TNF -  $\alpha$  suppression. *FASEB J.*, 16, 438-440.
- Malaguarnera, L. & Zorena, K. 2016. Neurodegeneration and neuroinflammation in diabetic retinopathy: potential approaches to delay neuronal loss. *Curr. Neuropharmacol.*, 14, 831-839.
- Medić, A., Jukić, T., Matas, A., Vukojević, K., Sapunar, A. & Znaor, L. 2017. Effect of preoperative topical diclofenac on intraocular interleukin-12 concentration and macular edema after cataract surgery in patients with diabetic retinopathy: a randomized controlled trial. *Croat. Med. J.*, 58, 49-55.
- Michaelides, M., Kaines, A., Hamilton, R. D., Fraser-Bell, S., Rajendram, R., Quhill, F., Boos, C. J., Xing, W., Egan, C. & Peto, T. 2010. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study): 12-month data: report 2. *Ophthalmology*, 117, 1078-1086. e2.
- Midena, E. & Pilotto, E. 2017. Emerging insights into pathogenesis. *Management of Diabetic Retinopathy*, 60, 16-27.
- Murakami, T. & Yoshimura, N. 2013. Structural changes in individual retinal layers in diabetic macular edema. *J. Diabetes Res.*, 2013.
- Nayak, K. & Misra, M. 2018. A review on recent drug delivery systems for posterior segment of eye. *Biomed. Pharmacother.*, 107, 1564-1582.
- Ng, D. S., Chiang, P. P., Tan, G., Cheung, C. G., Cheng, C. Y., Cheung, C. Y., Wong, T. Y., Lamoureux, E. L. & Ikram, M. K. 2016. Retinal ganglion cell neuronal damage in diabetes and diabetic retinopathy. *Clin. Experiment. Ophthalmol.*, 44, 243-250.
- Nguyen, Q. D., Shah, S. M., Heier, J. S., Do, D. V., Lim, J., Boyer, D., Abraham, P., Campochiaro, P. A. & Group, R.-S. 2009. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. *Ophthalmology*, 116, 2175-2181. e1.
- Nilsson, M., Von Wendt, G., Wanger, P. & Martin, L. 2007. Early detection of macular changes in patients with diabetes using Rarebit Fovea Test and optical coherence tomography. *Br. J. Ophthalmol.*, 91, 1596-1598.
- Nunes, S., Pereira, I., Santos, A., Bernardes, R. & Cunha-Vaz, J. 2010. Central retinal thickness measured with HD-OCT shows a weak correlation with visual acuity in eyes with CSME. *Br. J. Ophthalmol.*, 94, 1201-1204.

- Pascolini, D. & Mariotti, S. P. 2012. Global estimates of visual impairment: 2010. *Br. J. Ophthalmol.*, 96, 614-618.
- Pelosini, L., Hull, C. C., Boyce, J. F., Mchugh, D., Stanford, M. R. & Marshall, J. 2011. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. *Invest. Ophthalmol. Vis. Sci.*, 52, 2741-2748.
- Pinna, A., Blasetti, F., Ricci, G. D. A. & Boscia, F. 2017. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. *Eur. J. Ophthalmol.*, 27, 326-330.
- Potilinski, M. C., Lorenc, V., Perisset, S. & Gallo, J. E. 2020. Mechanisms behind retinal ganglion cell loss in diabetes and therapeutic approach. *Int. J. Mol. Sci.*, 21, 2351.
- Prager, S. G., Lammer, J., Mitsch, C., Hafner, J., Pemp, B., Scholda, C., Kundi, M., Schmidt - Erfurth, U. & Kriechbaum, K. 2018. Analysis of retinal layer thickness in diabetic macular oedema treated with ranibizumab or triamcinolone. *Acta Ophthalmol. (Copenh.)*, 96, e195-e200.
- Rangaraju, L., Jiang, X., Mcanany, J. J., Tan, M. R., Wanek, J., Blair, N. P., Lim, J. I. & Shahidi, M. 2018. Association between visual acuity and retinal layer metrics in diabetics with and without macular edema. *J. Ophthalmol.*, 2018.
- Rangasamy, S., Mcguire, P. G., Nitta, C. F., Monickaraj, F., Oruganti, S. R. & Das, A. 2014. Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy. *PLoS ONE*, 9, e108508.
- Rentiya, Z. S., Kherani, S., Usmani, B., Qazi, M. A., Sadiq, M. A., Iftikhar, M., Nguyen, Q. D., Shah, S. M., Sepah, Y. J. & Group, R.-S. 2020. Comparison of Retinal Layer Thickness in Eyes with Resolved Diabetic Macular Edema Receiving Ranibizumab with Normal Eyes. *Ophthalmologica*, 243, 27-36.
- Revel, F. B., Fayet, M. & Hagen, M. 2020. Topical Diclofenac, an Efficacious Treatment for Osteoarthritis: A Narrative Review. *Rheumatol. Ther.*, 1-20.
- Rodrigues, E. B., Farah, M. E., Bottós, J. M. & Aggio, F. B. 2016. Nonsteroidal anti-inflammatory drugs in the treatment of retinal diseases. *Retinal Pharmacotherapeutics*. Basel: Karger Publishers.
- Rodrigues, M. W., Cardillo, J. A., Messias, A., Siqueira, R. C., Scott, I. U. & Jorge, R. 2020. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial. *Graefes Archive for Clinical and Experimental Ophthalmology*, 258, 479-490.
- Russo, A., Costagliola, C., Delcassi, L., Parmeggiani, F., Romano, M. R. & Semeraro, F. 2013. Topical nonsteroidal anti-inflammatory drugs for macular edema. *Mediators Inflamm.*, 2013.
- Sanchez-Dalmau, B., Martinez-Lapiscina, E. H., Pulido-Valdeolivas, I., Zubizarreta, I., Llufrui, S., Blanco, Y., Sola-Valls, N., Sepulveda, M., Guerrero, A. & Alba, S. 2018. Predictors of vision impairment in multiple sclerosis. *PLoS ONE*, 13, e0195856.
- Schechter, B. A. & Trattler, W. 2010. Efficacy and safety of bromfenac for the treatment of corneal ulcer pain. *Adv. Ther.*, 27, 756-761.
- Schmidt-Erfurth, U., Garcia-Arumi, J., Bandello, F., Berg, K., Chakravarthy, U., Gerendas, B. S., Jonas, J., Larsen, M., Tadayoni, R. & Loewenstein, A. 2017. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). *Ophthalmologica*, 237, 185-222.
- Shaheer, M., Amjad, A. & Saleem, Z. 2019. Retinal ganglion cell complex changes after intravitreal bevacizumab for diabetic macular edema. *J. Coll. Phys. Surg. Pak. JCPSP*, 29, 426-429.
- Shapiro, A. 2016. Ocular drug delivery: targeting the posterior segment. *Retin. Today*, 25-27.

- Sivaprasad, S., Gupta, B., Crosby-Nwaobi, R. & Evans, J. 2012. Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. *Surv. Ophthalmol.*, 57, 347-370.
- Soheilian, M., Karimi, S., Ramezani, A., Montahai, T., Yaseri, M., Soheilian, R. & Peyman, G. A. 2015. Intravitreal diclofenac versus intravitreal bevacizumab in naive diabetic macular edema: a randomized double-masked clinical trial. *Int. Ophthalmol.*, 35, 421-428.
- Soheilian, M., Rabbanikhah, Z., Ramezani, A., Kiavash, V., Yaseri, M. & Peyman, G. A. 2010. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. *J. Ocul. Pharmacol. Ther.*, 26, 199-206.
- Sun, J. K., Radwan, S. H., Soliman, A. Z., Lammer, J., Lin, M. M., Prager, S. G., Silva, P. S., Aiello, L. B. & Aiello, L. P. 2015. Neural retinal disorganization as a robust marker of visual acuity in current and resolved diabetic macular edema. *Diabetes*, 64, 2560-2570.
- Suresh, S., Zunaina, E., Shatriah, I. & Azriani, A. 2012. Sensitivity and Specificity of HRT and OCT to Detect Diabetic Macular Edema. *J Diabetes Metab S*, 3, 2.
- Tan, G. S., Cheung, N., Simó, R., Cheung, G. C. & Wong, T. Y. 2017. Diabetic macular oedema. *Lancet. Diabetes. Endocrinol.*, 5, 143-155.
- Tang, J. & Kern, T. S. 2011. Inflammation in diabetic retinopathy. *Prog. Retin. Eye Res.*, 30, 343-358.
- Tomić, M., Vrabc, R., Poljičanin, T., Ljubić, S. & Duvnjak, L. 2017. Diabetic macular edema: Traditional and novel treatment. *Acta Clin. Croat.*, 56, 124-131.
- Totan, Y., Güler, E. & Gurağaç, F. B. 2016. Dexamethasone intravitreal implant for chronic diabetic macular edema resistant to intravitreal bevacizumab treatment. *Curr. Eye Res.*, 41, 107-113.
- Unlu, N., Kocaoglan, H., Sayin, F., Hazirolan, D., Demircan, S., Basci, N., Acar, M. A., Demir, N. M. & Duman, S. 2010. Penetration of topically applied diclofenac and ketorolac into the aqueous humour and subretinal fluid: randomized clinical trial. *Can. J. Ophthalmol.*, 45, 610-615.
- Van Dijk, H. W., Verbraak, F. D., Kok, P. H., Garvin, M. K., Sonka, M., Lee, K., Devries, J. H., Michels, R. P., Van Velthoven, M. E. & Schlingemann, R. O. 2010. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. *Invest. Ophthalmol. Vis. Sci.*, 51, 3660-3665.
- Van Meter, M. E. & Kim, E. S. 2010. Bevacizumab: current updates in treatment. *Curr. Opin. Oncol.*, 22, 586-591.
- Varela-Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García-Otero, X., Luzardo-Álvarez, A., Fernández-Ferreiro, A. & Otero-Espinar, F. J. 2020. Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations. *Pharmaceutics*, 12, 269.
- Villarreal, M., Ciudin, A., Hernández, C. & Simó, R. 2010. Neurodegeneration: an early event of diabetic retinopathy. *World J. Diabetes*, 1, 57.
- Vujosevic, S., Bini, S., Mídena, G., Berton, M., Pilotto, E. & Mídena, E. 2013. Hyperreflective intraretinal spots in diabetics without and with nonproliferative diabetic retinopathy: an in vivo study using spectral domain OCT. *J. Diabetes Res.*, 2013.
- Yamada, M., Ogata, M., Kawai, M., Mochizuki, H. & Mashima, Y. 2002. Topical diclofenac sodium decreases the substance P content of tears. *Arch. Ophthalmol.*, 120, 51-54.
- Yau, J. W., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A. & Grauslund, J. 2012. Global prevalence and major risk factors of diabetic retinopathy. *Diabetes Care*, 35, 556-564.

- Yun, C., Oh, J., Hwang, S.-Y., Kim, S.-W. & Huh, K. 2015. Subconjunctival hemorrhage after intravitreal injection of anti-vascular endothelial growth factor. *Graefe's Archive for Clinical and Experimental Ophthalmology*, 253, 1465-1470.
- Zhong, B. 2009. How to calculate sample size in randomized controlled trial? *J. Thorac. Dis.*, 1, 51.